Ecuador Medical Device Renewal: 5-Year Validity, the 90-Day Window and Automatic Renewal

1. Key takeaways

A registration certificate is valid for 5 years, and renewal must be filed at least 90 statutory periods (días término) before expiry and no earlier than 6 months before expiry. Article 38 provides that where the device has undergone no change of intended purpose, quality, safety or effectiveness during the validity period, no health alert or suspension has been imposed by ARCSA, and the application is filed at least 90 days before expiry, renewal is processed automatically and no material other than the application is required.

The automatic route is the most favourable provision in the whole regulation for existing holders. It removes the system certificate, the technical file and the sworn declaration from the renewal file, and it makes renewal cheap to maintain for a stable product.

The privilege is conditional, and the conditions are cumulative. The application must contain an express declaration that the device is not in any of the situations listed in Article 38. That declaration is what converts a passive filing into an asserted legal position, and it is the first document an inspector will ask to see.

2. Legal basis

The three cumulative conditions of Article 38: (1) the device has undergone no change or modification of intended purpose, quality, safety or effectiveness during the validity period; (2) no health alert or suspension has been imposed by ARCSA; (3) the holder files the renewal application at least 90 days in advance. Where all three are met, renewal is processed automatically with no requirement beyond the application, provided the application expressly declares that the device is in none of those situations.

3. Expert insights

Insight one: automatic renewal is the single most valuable provision for incumbent holders. Where the three conditions are met, the holder does not file a system certificate, a technical file or a sworn declaration; the application and its declaration are enough. That is unusual in Latin American markets and materially lowers the cost of holding a mature portfolio.

Insight two: the Article 37 window has two edges. At least 90 statutory periods before expiry, and no more than 6 months before expiry. Filing too early is as defective as filing too late, and both edges fall inside the same compliance diary entry.

Insight three: Article 39 names the three triggers that forfeit the automatic route. (1) a change of intended purpose, quality, safety or effectiveness made during the validity period without prior ARCSA approval; (2) a health alert or suspension; (3) filing outside the period set by Article 37. Any one of them removes the automatic renewal option.

Insight four: the supplementary documents in Article 39 apply situation by situation.

• Item (a), the system certificate, applies where there is an unapproved change or a late application: a current BPM certificate or equivalent; or a current ISO 13485 certificate or a stricter standard for imported devices; or an ISO 13485 certificate registered with ARCSA for domestic devices; or a current ISO 9001 certificate for pacifiers and bottles only;
• Item (b), the sworn declaration, signed by the legal representative or an authorised person and duly legalised, stating that no objection by ARCSA exists on the date of the renewal application; it applies only where a national or international health alert has been imposed, or the device has been suspended by the national health authority;
• Item (c), the technical and/or legal requirements supporting the change made, in accordance with instructions issued by ARCSA; it applies only where the device has been changed.

Insight five: the consequence of missing the window is a fresh start. Where renewal is not filed within the Article 37 period and the certificate has expired, the product may not be imported, manufactured or commercialised and a new registration procedure must be initiated. This is not a late renewal with a penalty; the file returns to the beginning.

Insight six: reclassification changes are free during the transition. Transitional provision two requires holders of reclassified products to request the reclassification through a change application, and provides that no fee is charged for that application. Reclassification during the transition period and ordinary renewal are separate channels, and mixing them wastes the waiver.

4. Practical recommendations

1. Set the renewal start date at the day the 6-month window opens, not at the 90-day minimum.
2. Build an evidence file for the no-change declaration, so that the Article 38 statement can be supported if challenged.
3. Control change approval strictly: any change made without ARCSA approval forfeits the automatic route.
4. Monitor alert status continuously; a single alert record triggers the sworn declaration requirement in Article 39, item (b).
5. Plan reclassification changes, which are free, separately from ordinary renewal, and use the transitional policy to reduce cost.

5. Verification checklist

• □ Renewal is scheduled to start on the day the 6-month window opens
• □ An evidence mechanism for the no-change declaration has been established (basis for the Article 38 statement)
• □ All changes have obtained prior ARCSA approval
• □ An alert status monitoring mechanism is in operation
• □ The consequence of late filing (a new registration) is recorded in the risk register
• □ Reclassification changes, the free channel, are planned separately from ordinary renewal

Regulatory information verified as of October 29, 2026

GRZAN core service lines

1. Global registration access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, together with pre-market registration pathway planning and submission execution across Latin America, Southeast Asia and the Middle East.
2. Authorized representative services: EU EC REP, UK RP, Swiss CH REP, Australian sponsor and US Agent holding and representation services, with support for neutral license-holder structures.
3. Quality system compliance: ISO 13485 establishment and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) drafting and remediation.
4. Clinical and evaluation support: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
5. Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why manufacturers choose GRZAN

• Local regulatory teams: target-market work is performed by locally licensed regulatory professionals, and submission dossiers are written directly in the local official language without secondary translation.
• Neutral license-holder structures: GRZAN offers holding arrangements that are not tied to any distribution channel, preventing registration certificates from being locked in by channel partners.
• Regional leverage: one technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance costs.
• Full lifecycle support: from classification determination and pathway design through dossier preparation, license holding, customs clearance, post-market vigilance and renewal.

Contact

• GRZAN provides registration support in Ecuador for manufacturers, importers and authorized representatives.
• Email: info@grzanglobal.com
• Service inquiries: Ecuador and Andean market registration plans, license-holder structure design, official fee and timeline estimation